Alnylam is facing a major challenger to its first approved drug, Onpattro, from Pfizer’s Vyndaqel just over a year into its launch. But the company now has another drug approval to bolster its portfolio—although analysts have expressed some concern about
read moreAfter former FDA commissioner Scott Gottlieb stepped down, the Trump administration is working to get a successor in place. Nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more. More: FDA Commissioner
read moreBristol-Myers Squibb’s Opdivo-Yervoy combo has changed the game in late-stage melanoma, but it’s hit a roadblock in expanding to post-surgery treatment. In patients with PD-L1 levels below 1%, the duo couldn’t beat solo Opdivo at staving off recurrence. More: Bristol's
read moreIn August Torrent Pharmaceuticals recalled dozens of lots of over-the-counter cough syrups, nasal sprays and rectal suppositories that put children and adults at risk of bacterial infection. Now the FDA has lambasted the Indian drugmaker for a poorly designed water
read moreMerck’s PD-1 superstar Keytruda has been growing exponentially thanks mainly to its lead in newly diagnosed non-small cell lung cancer. However, recent successes for immuno-oncology competitors could put some pressure on its near-term growth, one analyst says. But worry not,
read more96.7% of men in the relugolix trial achieved sustained testosterone suppression to castrate levels. More: Myovant successful in Phase III prostate cancer trial Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals